Novartis has embraced a bold strategy to drive a company-wide digital transformation. Our objective is to position Novartis as an industry leader by proactively adopting digital technologies that foster innovative approaches to hasten drug discovery and development. By utilizing both internal and external Research & Development data with the power of data science, predictive models, generative AI, and machine learning, our objective is to identify new targets, create more effective therapeutic molecules, better predict drug pharmacokinetics and safety risks, refine clinical trial design, and significantly shorten development cycles. The Artificial Intelligence & Computational Sciences (AICS) team leads Biomedical Research (BR) in exploring and applying advanced AI and ML methodologies to generate novel drug discovery insights, and to speed and improve drug discovery efficiency whilst focusing on patients' needs. AICS partners with drug discovery teams, raises the level of AI expertise across BR and ensures that BR science keeps up with the rapidly evolving ecosystem of AI technologies by connecting with AI leaders in academia and industry. This roleâ withinâ theâ AI Methodsâ group of AICS will be tasked with critical assessment of the model landscape, identifying opportunities for methodological innovation, and building the right AI approaches, algorithms, models and workflows to maximize impact on key domains areas of biomedical research that will potentially lead to developing better drugs, faster.